טוען...
Bilirubin, a new therapeutic for kidney transplant?
In patients with end-stage renal disease, kidney transplantation has been associated with numerous benefits, including increased daily activity, and better survival rates. However, over 20% of kidney transplants result in rejection within five years. Rejection is primarily due to a hypersensitive im...
שמור ב:
| הוצא לאור ב: | Transplant Rev (Orlando) |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6535229/ https://ncbi.nlm.nih.gov/pubmed/29983261 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.trre.2018.06.003 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|